Experimental Treatment for Rheumatoid Arthritis

Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.

Pharmaceutical medication involved
Recruiting patients only

Drug - Pirfenidone

Pirfenidone three times daily (2403 mg) for 52 weeks

Drug - Placebo

Placebo three times daily for 52 weeks

Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)